Healthcare IT - DiagnosticsLOCATIONS
New Haven, CTEXITED
HistoRx built predictive companion diagnostic tests that rapidly identify, validate and spatially map proteomic biomarkers, and diseases in tissue samples.
Brook was the lead investor in HistoRx and helped build a business around commercializing a technology originally developed at Yale Medical School. Brook helped the business grow its technology portfolio and revenue base, and managed the M&A process leading to the Company’s purchase by Genoptix, a division of Novartis, in 2012. The business’ novel biomarkers continue to help today’s physicians diagnose and create better care regimens, primarily in the oncology market.